MAPK
Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
p38 MAPK Inhibitor
Gossypetin is a hexahydroxylated flavonoid that primarily targets the p38 MAPK signaling pathway by inhibiting mitogen-activated protein kinase kinases MKK3 and MKK6. This inhibition effectively attenuates the MKK3/6-p38 signaling pathway, leading to multiple pharmacological effects, including antioxidant, antibacterial, and anticancer activities. Gossypetin is of interest in research exploring therapeutic applications against various diseases mediated by p38 MAPK signaling dysregulation. -
p38 Inhibitor
N-Acetylmuramic acid is a key component of the bacterial cell wall peptidoglycan, targeting the p38 MAPK signaling pathway. It plays a critical role in maintaining cell shape and integrity in bacterial species, particularly Bacteroides forsythus, while also inhibiting spore germination through the inhibition of hexosaminidase and core enzymes. Additionally, N-acetylmuramic acid exhibits significant anti-inflammatory activity, making it a valuable reagent in studies of cellular proliferation and inflammatory responses. This compound is noted for its oral bioactivity. -
NF-κB p65 Inhibitor, p38 MAPK Inhibitor
PSMα3 is an inhibitor of NF-κB p65 and p38 MAPK, playing a significant role in modulating inflammatory pathways. This compound forms membrane pores and interacts with the human insulin B chain, inhibiting insulin aggregation and contributing to cytotoxic effects through α-type amyloid-like fibril formation. PSMα3 is valuable for research on spondyloarthritis, rheumatoid arthritis, insulin-derived amyloidosis, and infections caused by Staphylococcus aureus. -
p38 MAPK Inhibitor
Bisabolangelone is a potent inhibitor of the p38 MAPK pathway. Isolated from the roots of Osterici Radix, this sesquiterpene derivative demonstrates significant anti-inflammatory activity by inhibiting LPS-stimulated inflammation through the blockade of the NF-kappaB and MAPK signaling pathways in macrophages. Additionally, Bisabolangelone exhibits anti-ulcer activities, making it a valuable tool in studies related to inflammation and gastrointestinal disorders. -
p38 MAPK Inhibitor
p38 MAP Kinase Inhibitor III is a potent inhibitor of p38 MAPK, with an IC50 value of 0.9 μM. This compound also effectively reduces the release of pro-inflammatory cytokines, specifically IL-1β and TNF-α, with IC50 values of 0.37 μM and 0.044 μM, respectively. p38 MAP Kinase Inhibitor III is valuable for research in inflammation, signaling pathways, and related therapeutic applications. -
p38α Inhibitor
Emprumapimod is a selective inhibitor of p38α MAPK that exhibits potent oral activity. By directly inhibiting LPS-induced IL-6 production in RPMI-8226 cells (IC50=100 pM), it presents significant anti-inflammatory properties. This compound is applicable in research studies focused on dilated cardiomyopathy and acute inflammatory pain, making it a valuable tool for elucidating the role of p38α in various inflammatory conditions. -
MEK1 Inhibitor
Nedometinib is a selective MEK1 inhibitor, demonstrating an IC50 of 135 nM. By inhibiting phosphorylated ERK (p-ERK) in the MAPK signaling pathway, Nedometinib exhibits notable anticancer activity against squamous cell carcinoma. This compound is valuable for research applications related to dermatosis and neurofibromatosis. -
TAK1-MKK3 PPI Inhibitor
(R)-STU104 is a selective inhibitor of the TAK1-MKK3 protein-protein interaction, demonstrating potent activity with IC50 values of 0.58 μM for TNF-α and 4.0 μM for MKK3 phosphorylation. By binding to MKK3, (R)-STU104 effectively disrupts the TAK1-mediated phosphorylation of MKK3, subsequently inhibiting the TAK1/MKK3/p38/MnK1/MK2/eIF4E signaling pathway. This compound is a valuable tool for investigating the molecular mechanisms underlying ulcerative colitis and related inflammatory conditions. -
p38α MAPK Inhibitor
p38α Inhibitor 2 is a highly selective inhibitor of the p38α mitogen-activated protein kinase (MAPK), exhibiting a pIC50 value of 9.6. This compound demonstrates potent inhibition of the hERG ion channel with an IC50 of 27 μM. Additionally, p38α Inhibitor 2 shows an excellent selectivity profile, demonstrating less than 30% inhibition across a panel of 51 protein kinases at a concentration of 10 μM, indicating its potential utility in various biological research applications focused on inflammation and stress responses. -
p38α Inhibitor
SD-169 is an orally active ATP-competitive inhibitor of p38α MAPK, exhibiting an IC50 of 3.2 nM. This compound also demonstrates weak inhibition of p38β MAPK with an IC50 of 122 nM. SD-169 has been shown to impede the development and progression of diabetes by inhibiting T cell infiltration and activation, making it valuable for research in immunology and metabolic disease pathways. -
p38 MAPK Inhibitor
p38 MAPK-IN-4 is a selective inhibitor of p38 mitogen-activated protein kinase (MAPK) with an IC50 of 35 nM. This compound modulates the p38 MAPK signaling pathway, which is critical in cellular responses to stress and inflammation. It is suitable for research applications investigating inflammatory diseases, cancer, and other conditions associated with p38 MAPK activity. -
p38α MAPK Inhibitor
p38 MAP Kinase Inhibitor IV is a selective ATP-competitive inhibitor targeting p38α MAPK, exhibiting IC50 values of 0.13 μM and 0.55 μM for p38α and p38β MAPK, respectively. This compound plays a crucial role in modulating cellular responses to stress and inflammation by inhibiting the p38 MAPK signaling pathway. It is utilized in research applications focused on therapeutic interventions for inflammatory diseases and various cancer models. -
Raf/MEK/MAPK Pathway Inhibitor
2-Bromoaldisine is a pyrrole alkaloid that acts as a potent inhibitor of the Raf/MEK/MAPK signaling pathway. It is known to effectively suppress HIV-1 vector infection. This compound is valuable for research applications focused on cancer biology and viral pathogenesis, allowing investigators to study the effects of Raf/MEK/MAPK pathway modulation on cell proliferation and viral replication. -
MEK Inhibitor
MEK-IN-9 is a selective inhibitor of the MEK (mitogen-extracellular signal-regulated kinase) pathway. This compound has been shown to induce the expression of the tumor suppressor proteins p15 and p27, contributing to its anti-proliferative effects. MEK-IN-9 is suitable for research focusing on renal adenocarcinoma and colorectal cancer, making it a valuable tool for studying the mechanisms of tumor growth and potential therapeutic interventions. -
MEK1/2 inhibitor
AS703026 is a novel, selective, orally bioavailable MEK1/2 inhibitor that inhibits growth and survival of MM cells and cytokine-induced osteoclast differentiation. -
p38 MAPK inhibitor
LY2228820 is a novel and potent p38MAPK inhibitor with potent antiinflammatory activity. -
RAF/VEGFR Inhibitor
RAF265 (CHIR-265) is an oral, highly selective RAF and VEGFR kinase inhibitor, which is to control or normalize VEGFR-2 along with the inhibition of B-raf and c-Raf mutation to prevent cancers. -
RAF/VEGFR Inhibitor
Raf265 derivative is a derivative of Raf265 that is an oral, highly selective RAF and VEGFR kinase inhibitor with IC50 of of 5 to 10 μM. -
p38 MAPK inhibitor
Pexmetinib is a potent inhibitor of cytokine synthesis, via the dual inhibition of p38 mitogen-activated protein kinase (MAPK), and Tie2/Tek receptor tyrosine kinase. -
p38 MAPK inhibitor
VX-745 is a small-molecule inhibitor of MAPK that is reported to be active against several isotypes of p38 MAPK, including p38α, p38βand p38γ . -
p38 MAPK inhibitor
SKF 86002 Dihydrochloride is inhibitor of p38 MAP kinase (IC50 = 0.1 - 1 uM). Potently inhibits LPS-induced IL-1 and TNF-α production in human monocytes (IC50 = 1 uM). -
p38 MAPK inhibitor
SB 203580 hydrochloride (Adezmapimod hydrochloride) (RWJ 64809 hydrochloride) is a widely used p38 MAPK inhibitor.
-
MAPKAPK2(MK2) inhibitor
MK2-IN-1 hydrochloride is a potent and selecitve MAPKAPK2(MK2) inhibitor(IC50=0.11 uM) with a non-ATP competitive binding mode. -
ALK/MET inhibitor
Ensartinib hydrochloride (X-396 hydrochloride) is a potent and dual ALK/MET inhibitor with IC50s of <0.4 nM and 0.74 nM, respectively. -
Raf kinase inhibitor
B-Raf inhibitor 1 dihydrochloride is a potent Raf kinase inhibitor with Kis of 1 nM, 1 nM, and 0.3 nM for B-RafWT, B-RafV600E, and C-Raf, respectively. -
p38α MAPK inhibitor
MW-150 hydrochloride (MW01-18-150SRM hydrochloride) is a selective, CNS penetrant, and orally active inhibitor of p38α MAPK with a Ki of 101 nM. -
p38α MAPK inhibitor
MW-150 dihydrochloride dihydrate (MW01-18-150SRM dihydrochloride dihydrate) is a selective, CNS penetrant, and orally active inhibitor of p38α MAPK with a Ki of 101 nM. -
p38α MAPK inhibitor
BMS-582949 hydrochloride is an orally active and highly selective p38α MAPK inhibitor, with an IC50 of 13 nM. -
p38 MAPK α/β inhibitor
Ralimetinib (LY2228820) is a potent and selective, ATP-competitive inhibitor of p38 MAPK α/β, with IC50s of 5.3 and 3.2 nM, respectively. -
NF-κB inhibitor
Urolithin B is one of the gut microbial metabolites of ellagitannins, and has anti-inflammatory and antioxidant effects. Urolithin B is also a regulator of skeletal muscle mass. -
JNK inhibitor
CC-90001 is a potent and selective JNK inhibitor. CC-90001 shows 12.9-fold selectivity for JNK1 over JNK2 in a cell-based model. CC-90001 can be used for the research of idiopathic pulmonary fibrosis -
raf kinase inhibitor
Raf inhibitor 2 is a potent raf kinase (IC50<1.0 μM) inhibitor, compound 32, extracted from patent EP1003721B1. Raf inhibitor 2 can be used for cancer research. -
TAK1 Inhibitor
5Z-7-Oxozeaenol is a selective and irreversible inhibitor of TAK1, exhibiting an IC50 of 8 nM. This compound also inhibits VEGF-R2 with an IC50 of 52 nM, demonstrating potential applications in anti-protozoan research and studies related to inflammation and tumorigenesis. Its unique mechanism of action makes it a valuable tool for exploring signaling pathways associated with cellular stress responses and vascular biology. -
SOS1 Inhibitor
RMC-0331 is a potent and selective inhibitor of SOS1, designed for oral bioavailability. It effectively blocks RAS activation by disrupting the interaction between RAS and SOS1, making it a valuable tool compound for in vivo studies. This compound is suitable for exploring RAS signaling pathways and investigating therapeutic applications in cancer research. -
SOS1 Inhibitor
SOS1-IN-14 is a potent and selective inhibitor of SOS1, demonstrating an IC50 value of 3.9 nM. This orally active compound is absorbed in the intestine through a P-glycoprotein-mediated efflux mechanism. SOS1-IN-14 is primarily utilized in research on KRAS-mutated cancers, showcasing superior tumor suppression capabilities compared to alternative therapies. -
SOS1/KRAS Inhibitor
SAH-SOS1A TFA is a peptide-based inhibitor targeting the SOS1-KRAS protein interaction. It exhibits nanomolar affinity for both wild-type and various mutant KRAS forms, including G12D, G12V, G12C, G12S, and Q61H (EC50 = 106-175 nM). By directly disrupting nucleotide association, SAH-SOS1A TFA effectively impairs KRAS-driven cancer cell viability and inhibits the downstream ERK-MAPK phosphosignaling cascade, making it a valuable tool for research in cancer biology. -
SOS1 Inhibitor
SOS1-IN-15 is a potent SOS1 inhibitor with an IC50 value of 5 nM, designed to specifically target and inhibit SOS1 activity. Its strong inhibitory effect makes it a promising candidate for research into KRAS-driven cancers, facilitating the understanding of oncogenic signaling pathways and development of targeted therapeutic strategies.
